Cargando…

Vandetanib (ZD6474) in the Treatment of Medullary Thyroid Cancer

Vandetanib (ZD6474) is an orally bioavailable small molecule tyrosine kinase inhibitor of multiple growth factor receptors, including RET (Rearrange during transfection), vascular endothelial growth factor receptor-2 (VEGFR-2) and epidermal growth factor receptor (EGFR). The activity against RET and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deshpande, Hari, Roman, Sanziana, Thumar, Jaykumar, Sosa, Julie Ann
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Libertas Academica 2011
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3153121/ https://www.ncbi.nlm.nih.gov/pubmed/21836817 http://dx.doi.org/10.4137/CMO.S6197

Ejemplares similares

Vandetanib for the Treatment of Metastatic Medullary Thyroid Cancer
por: Degrauwe, Nils, et al.
Publicado: (2012)

Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer
por: Flanigan, Jaclyn, et al.
Publicado: (2010)

Clinical utility of vandetanib in the treatment of patients with advanced medullary thyroid cancer
por: Deshpande, Hari, et al.
Publicado: (2011)

Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma
por: Yoshikawa, D, et al.
Publicado: (2009)

Phase I Study of Cetuximab, Irinotecan, and Vandetanib (ZD6474) as Therapy for Patients with Previously Treated Metastastic Colorectal Cancer
por: Meyerhardt, Jeffrey A., et al.
Publicado: (2012)

ZD6474 – clinical experience to date
por: Heymach, J V
Publicado: (2005)

Vandetanib (Zactima, ZD6474) Antagonizes ABCC1- and ABCG2-Mediated Multidrug Resistance by Inhibition of Their Transport Function
por: Zheng, Li-sheng, et al.
Publicado: (2009)

Vandetanib (ZD6474) induces antiangiogenesis through mTOR–HIF-1 alpha–VEGF signaling axis in breast cancer cells
por: Li, Ling, et al.
Publicado: (2018)

Role of vandetanib in the management of medullary thyroid cancer
por: Brassard, Maryse, et al.
Publicado: (2012)

Autophagy inhibition induces enhanced proapoptotic effects of ZD6474 in glioblastoma
por: Shen, J, et al.
Publicado: (2013)

Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes
por: Fallahi, Poupak, et al.
Publicado: (2019)

ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein
por: Freshney, R I
Publicado: (2007)

ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein
por: Mi, Y, et al.
Publicado: (2007)

ZD6474 – a novel inhibitor of VEGFR and EGFR tyrosine kinase activity
por: Ryan, A J, et al.
Publicado: (2005)

Reply: ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein
por: Mi, Y, et al.
Publicado: (2007)

ZD6474, a new treatment strategy for human osteosarcoma, and its potential synergistic effect with celecoxib
por: Liu, Jiani, et al.
Publicado: (2015)

The tyrosine kinase inhibitor ZD6474 inhibits tumour growth in an intracerebral rat glioma model
por: Sandström, M, et al.
Publicado: (2004)

ZD6474 in combination with paclitaxel and UVB irradiation enhances the antiproliferative effect and apoptosis on breast carcinoma
por: Sarkar, S, et al.
Publicado: (2009)

Vandetanib in Advanced Medullary Thyroid Cancer: Review of Adverse Event Management Strategies
por: Grande, Enrique, et al.
Publicado: (2013)

Phototoxic drug eruption induced by vandetanib used for the treatment of metastatic medullary thyroid cancer()
por: Bostan, Ecem, et al.
Publicado: (2022)

Efficacy and Tolerability of Pharmacotherapy Options for the Treatment of Medullary Thyroid Cancer
por: Deshpande, H. A., et al.
Publicado: (2012)

Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension
por: Milling, Rikke Vilsbøll, et al.
Publicado: (2018)

Prognostic Value of Serum Tumor Markers in Medullary Thyroid Cancer Patients Undergoing Vandetanib Treatment
por: Werner, R.A., et al.
Publicado: (2015)

Selective use of vandetanib in the treatment of thyroid cancer
por: Fallahi, Poupak, et al.
Publicado: (2015)

Patterns of thyroid hormone levels in pediatric medullary thyroid carcinoma patients on vandetanib therapy
por: Lodish, Maya, et al.
Publicado: (2015)

Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect
por: Højer Wang, Linnea, et al.
Publicado: (2023)

Vandetanib for the Management of Advanced Medullary Thyroid Cancer: A Real-World Multicenter Experience
por: Kim, Mijin, et al.
Publicado: (2020)

Targeted therapy against EGFR and VEGFR using ZD6474 enhances the therapeutic potential of UV-B phototherapy in breast cancer cells
por: Sarkar, Siddik, et al.
Publicado: (2013)

Prognostic Value of Serum Tumor Markers in Medullary Thyroid Cancer Patients Undergoing Vandetanib Treatment: Erratum
Publicado: (2016)

Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer
por: Del Rivero, Jaydira, et al.
Publicado: (2018)

Effect of Vandetanib Treatment on Cystic Changes in the Liver following Metastasis from Medullary Thyroid Carcinoma
por: Matsui, Ai, et al.
Publicado: (2022)

Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours
por: Checkley, D, et al.
Publicado: (2003)

Intravoxel Incoherent Motion Diffusion-weighted Magnetic Resonance Imaging for Monitoring the Early Response to ZD6474 from Nasopharyngeal Carcinoma in Nude Mouse
por: Cui, Yanfen, et al.
Publicado: (2015)

Axitinib: The evidence of its potential in the treatment of advanced thyroid cancer
por: Deshpande, Hari A, et al.
Publicado: (2010)

Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial
por: Kreissl, Michael C., et al.
Publicado: (2020)

ZD6474 attenuates TGF-β1-induced fibrosis in human Tenon fibroblasts and inhibits neovascularization via AKT-mTOR signaling pathway
por: Liu, Wenting, et al.
Publicado: (2022)

Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model
por: Carra, Silvia, et al.
Publicado: (2021)

Vandetanib
por: Vozniak, J. Michael, et al.
Publicado: (2012)

Vandetanib induces a marked anti-tumor effect and amelioration of ectopic Cushing’s syndrome in a medullary thyroid carcinoma patient
por: Bseiso, Hashem, et al.
Publicado: (2016)

Volumetric and texture analysis of pretherapeutic (18)F-FDG PET can predict overall survival in medullary thyroid cancer patients treated with Vandetanib
por: Werner, Rudolf A., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9940se6t0bjio8pon56f79qcct